Диссертация (1154700), страница 16
Текст из файла (страница 16)
DNA methylation of tumor suppressor genes in clinical remission predicts therelapse risk in acute myeloid leukemia / Agrawal S, Unterberg M, Koschmieder S, [et al.]// Cancer Res. — 2007. — Vol. 67(3). — P.1370-1377.115. Donnez, J. Uterine fibroid management: from the present to the future / J.Donnez, M. Dolmans // Human Reproduction Update. — 2016. — Vol. 22, Issue 6. —P. 665–686.116.
Evans, P. Georgetown university-providence hospital family practiceresidency program / Evans P. // Fam. Physicians. — 2007. — Vol. 75(10). — P. 1503.117. Epidemiology of Uterine Myomas: A Review / Sparic R, Mirkovic L, MalvasiA, Tinelli A. // International Journal of Fertility & Sterility. — 2016 — Vol.
9(4). —P.424-435.118. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) genein human colorectal cancer / Aguilera O., Fraga M.F., Ballestar E. [et al.] // Oncogene. —2006. — Vol. 25. — P. 4116-4121.119. Epigenetic marks by DNA methylation specific to stem, germ and somaticcells in mice / Shiota K, Kogo Y, Ohgane J, [et al.] // Genes Cells. — 2002. — Vol. 7. —P.961–969.120. Epigenetic mechanisms of pulmonary hypertension / Kim GH, Ryan JJ,Marsboom G, Archer SL.
// Pulm Circ. — 2011. — Vol. 1(3). — P.347-356.121. Epigenetic regulation of phosphodiesterases 2a and 3a underlies compromisedb-adrenergic signaling in an iPSC model of dilated cardiomyopathy / Wu et al // Cell.Stem. Cell. — 2015. — Vo. 17. —P. 89–100.122. Epigenetics of the vascular endothelium / Matthew Shu-Ching Yan,Charles C. Matouk, Philip A. Marsden // Journal of Applied Physiology.
—2010. —Vol. 109. — №. 3. — Р.916-926103123. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, andpotential / Kazanets A. [et al.] // Biochim. Biophys. Acta -Rev. Cancer. The Authors. —2016. — Vol. 1865(2). — P.275-288.124. Estrogen and progesterone receptor status affect genome-wide DNAmethylation profile in breast cancer / Lian Li , Kyoung-Mu Lee, Wonshik Han [et al.] //Human Molecular Genetics.
— 2010. — Vol. 19. —№. 21. — Р.4273-4277.125. Estrogen receptor alpha and beta expression in uterine leiomyoma frompremenopausal women / Jakimiuk A. L., Bogusiewicz M., Tarkowski R. [et al.] // Fertil.Steril. — 2004. — Vol. 82 (3). — P. 1244– 1249.126. “Estrogen receptor-alpha regulates the degradation of insulin receptorsubstrates 1 and 2 in breast cancer cells / Morelli C, Garofalo C, Bartucci M, Surmacz E.// Oncogene. — №22. — P.4007–4016.127. Expression pattern of Wnt inhibitor factor 1(Wif1) during the development inmouse CNS / Hu Y-A, Gu X, Liu J. [et al.] // Gene Expression Patterns. — 2008.
— Vol.8(7-8). — P.515-552.128. Expression of progesterone receptor form A and B mRNAs in uterineleiomyoma / J. Fujimota, R. Hirose, S. Ichigo, [et al.] // Tumor Biology. — 1998—Vol. 19. — №2. — Р.126–131.129. Faerstein, E. Risk factors for uterine leiomyoma: a practice-based case-controlstudy. II. Atherogenic risk factors and potential sources of uterine irritation / Faerstein E,Szklo M, Rosenshein NB.
// Am J Epidemiol. — 2001. — №153 — Р.11–19.130. Falcone, T. Surgical management of leiomyomas for fertility or uterinepreservation / Falcone, T.; Parker, W.H. // Obstet. Gynecol. — 2013. — Vol. 121 —Р.856–868.131. Feinberg, A.P. The epigenetic progenitor origin of human cancer / Falcone, T.;Parker, W.H. // Nat. Rev. Genet. — 2006.
— Vol. 7. — P. 21-33.132. Feinberg, A.P. The history of cancer epigenetics / Feinberg A.P., Tycko B. //Nat. Rev. Cancer. — 2004. — Vol. 4. — P. 143-153.133. Female reproductive disorders: the roles of endocrine-disrupting compoundsand developmental timing / Fertil Steril. — 2008. — Vol. 90. — P.911-940.104134. Flake, G. P. Etiology and pathogenesis of uterine leiomyomas: a review /Flake G. P., Andersen, J., Dixon, D. // Environmental Health Perspectives. — 2003. —Vol. 111(8). — P.
1037–1054.135. Genic expression of the uterine leiomyoma in reproductive-aged women aftertreatment with goserelin / Borsari R, Bozzini N, Junqueira CR. // Fertil Steril. — 2010 —Vol. 94(3). — P.1072-1077.136. Genome-Wide DNA Methylation Analysis Reveals a Potential Mechanism forthe Pathogenesis and Development of Uterine Leiomyomas / Ryo Maekawa, Shun Sato[et al.] // PLoS One. — 2013 — Vol. 8(6): e66632.Published online 2013 Jun 20.137.
Genome-wide survey reveals predisposing diabetes type 2-related DNAmethylation variations in human peripheral blood / Toperoff G, Aran D, Kark JD, [et al.]// Hum Mol Genet. — 2012. — Vol. 21(2). — P.371-383.138. Genomics of uterine leiomyomas: insights from high-throughput sequencing/ Mehine M, Mäkinen N, Heinonen HR, [et al.] // Fertil Steril. — 2014. — Vol. 102(3). —P.621.139. Georgios, A. Uterine Myomas: Recent Advances in their Treatment /Georgios, A.; Georgios, D J. // Gynecol. Women’s Health. — 2016. — №1.
— P.555-560.140. Gross K. L. Genetics and the development of fibroids / Gross K. L., C. C.Morton // Clinical Obstetrics and Gynecology. — 2001. — Vol. 44. — P. 335– 349.141. Growth and differentiation signals by the insulin-like growth factor 1 receptorin hemopoietic cells are mediated through different pathways / Valentinis B, Romano G,Peruzzi F. [ et al.] // J Biol Chem. — 1999. — Vol. 274. — Р.12423–12430.142. Gross, K.L. Genetics and the development of fibroids / Gross K.L.,Morton C.C. // Clin.
Obstet. and Gynecol. — 2001. — Vol. 44 — Р.335-349.143. Growth of uterine leiomyomata among premenopausal black and whitewomen / Peddada SD, Laughlin SK, Miner K, [et al.] // Proc Natl Acad Sci U S A. —2008. — Vol. 105. — P. 19887-92.144. Guo, X. A mediator lost in the war on cancer / Guo X, Wang XF.
// Cell —2012. — Vol. 151. — P.927-9.145. Hall P.A. Assessment of cell proliferation markers with particular emphasis105on Ki-67 and PCNA / Hall P.A. // A report for DAKO A/S.-London,1993.146. Hendrich, B. Human disease with underlying defects in chromatin structureand modification / Hendrich B., Bickmore W. // Hum. Mol.
Genet. — 2001. — Vol. 10. —P. 2233-2242.147. High cumulative incidence of uterine leiomyoma in black and white women:Ultrasound evidence / Baird, D.D.; Dunson, D.B.; Hill, M.C. [et al.] // Am. J. Obstet.Gynecol. — 2003 — Vol. 188 — P.100–107.148. . Histone deacetylase 6 regulates estrogen receptor alpha in uterine leiomyoma/ Wei LH, Torng PL, Hsiao SM.[et al.] // Reprod Sci. — 2011.
— Vol. 18(8). — P.755762.149. HMGIC expression in human adult and fetal tissues and in uterineleiomyomata, Genes, Chromosomes and Cancer / G. J. Gattas, B. J. Quade, R. A. Nowak,C. C. Morton // Obstetrics and Gynecology International. — 1999. — Vol. 25. — P. 316–322.150. HMGA2 and p14Arf: major roles in cellular senescence of fibroids andtherapeutic implications / D. N. Markowski, B.
M. Helmke, G. Belge [et al.] // AnticancerResearch. 2011. — Vol. 31. — №3. — Р.753–761.151. Hoellen, F. New Concepts in the Therapeutc Management of Myoma /Hoellen F., Bohlmann M.K. // EMJ Reprod. Health. — 2015. — №1. — Р.87–94.152. Holliday, R. Mechanisms for the control of gene activity during development/ Holliday R. // Biol. Rev. Camb. Philos. Soc. — 1990.
— Vol. 65(4). — Р.431-471.153. Holliday, R. Mutations and epimutations in mammalian cells Holliday R. //Mut. Res. — 1991. — Vol.250. — P.351–363.154. Horsthemke, B. Epimutations in human disease / Horsthemke B. // Curr. Top.Microbiol. Immunol. — 2006. — Vol.310. — P.45–59.155. Horsthemke, B., Assisted reproduction: the epigenetic perspective /Horsthemke B., Ludwig M. // Hum. Reprod. Upd. — 2005. — Vol.11. — P.473–482.156. Identification of c-MYC as a target of the APC pathway. / He TC, Sparks AB,Rago C.
[et al.] // Science. — 1998. — Vol. 281. — P.1509-1512.157. Immunohistochemical study of the prolifer- ation index, oestrogen receptors106and progesterone receptors A and B in leiomyomata and normal myometrium during themenstrual cycle and under gonadotrophin-myometrium during the men- strual cycle andunder gonadotrophin-releasing hormone agonist therapy / Nisolle M., Gillerot S.,Casanas-Roux F.
[et al.] // Hum. Reprod. — 1999. — Vol. 14. — P. 2844–2850.158. Inhibition of canonical WNT signaling attenuates human leiomyoma cellgrowth / Masanori Ono, Ping Yin, Antonia Navarro [et al.] // Fertility and Sterility. —2014 — Vol. 101 — № 5. — Р.1441-1449.159. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case /Quade B.J., Dal Cin P., Neskey D.M. [et al.] // Mol. Pathol.
— 2002. — Vol. 15. —№3.— P. 351–356.160. Jamaluddin, MS. Hyperhomocysteinemia, DNA methylation and vasculardisease / Jamaluddin MS, Yang X, Wang H. // Clin Chem Lab Med. — 2007. —Vol. 45(12). — P.1660-1666.161. Jean-Pierre Issa. Epigenetic Therapy [Электронный ресурс]. — Режимдоступа: http://www.pbs.org/wgbh/nova/body/epigenetic-therapy.html.162.
Jichan, Nie. Promoter hypermethylation of progesterone receptor isoform B(PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and ademethylation agent / Jichan Nie, Xishi Liu, Guo SW. // Reprod Sci. —2010 — Vol. 17(11). — P.995-1005.163. Jones, PA. DNA methylation and cancer / Jones PA. // Oncogene. — 2002. —Vol. 21(35). — P.5358-5360.164. Johnson, C.A. Chromatin modification and disease / Johnson C.A.
// J MedGenet. — 2000. — Vol. 37. — P. 905-915.165. Khan, A.T. Uterine fibroids: Current perspectives / Khan, A.T.; Shehmar, M.;Gupta, J.K. // Int. J. Women’s Health. — 2014. — Vol. 6. — P.95–114.166. Kolankaya, A. Myomas and assisted reproductive technologies: when andhow to act? / Kolankaya A., Arici A. // Obstet Gynecol Clin North Am. — 2006. — №33. — P. 145–152.167. Kumaki, Y. QUMA: quantification tool for methylation analysis / Kumaki Y.,Oda M., Okano M // Nucleic Acids Res. — 2008. — Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
